A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy
Latest Information Update: 15 Mar 2024
At a glance
- Drugs Ligelizumab (Primary)
- Indications Peanut hypersensitivity
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 11 Jan 2024 Status changed from active, no longer recruiting to discontinued. (Study terminated by sponsor).
- 29 Dec 2023 This trial has been discontinued in France (Date of the global end of the trial: 27-Nov-2023).
- 13 Dec 2023 Planned End Date changed from 21 May 2025 to 14 Dec 2023.